Q-omics provides the consensus-scored TRIM51JP profile across patient tissues and cancer cell-line models. TRIM51JP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TRIM51JP is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TRIM51JP RNA expression shows 6,753 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KIRC as cancer lineages where TRIM51JP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM51JP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM51JP survival associations across molecular data types. TRIM51JP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM51JP RNA expression–survival associations across cancer types. High TRIM51JP expression shows unfavorable associations in STAD, UCEC, KIRC, READ and THCA, but favorable associations in ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for TRIM51JP RNA expression.
This table summarizes TRIM51JP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM51JP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM51JP shows lower tumor expression in KIRC, THCA, PAAD, KICH and HNSC and higher tumor expression in UCEC. The KIRC box plot shows higher TRIM51JP RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p < 0.001).
This table shows molecular features associated with TRIM51JP in patient tissues and cancer cell lines. In patient samples, TRIM51JP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
